 Home > Biochemistry News > Biotechnology News > More than $6 billion to develop IgM antibody therapy, Sanofi reaches cooperation

More than $6 billion to develop IgM antibody therapy, Sanofi reaches cooperation

 Last Update: 2022-04-23
 Source: Internet
 Author: User

Tags

igg igm antibodies

lps inflammation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Sanofi and IGM Biosciences announced a research and development collaboration to develop agonists against three oncology targets and three immunology/inflammation targets using IGM Biosciences' unique IgM antibody technology platform

IgM is a type of antibody produced in the body, and unlike normal IgG antibodies, they have 10 sites where they can bind to antigens, a feature that increases their affinity for their targets

▲The different structures of IgM and IgG antibodies (Image source: IGM Biosciences official website)

Under the partnership agreement, IGM will receive an upfront payment of $150 million

In terms of immunology/inflammation collaboration, IGM will be responsible for R&D activities until the completion of Phase 1 clinical trials, and Sanofi will be responsible for subsequent development

Dr.

References:

[1] Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express more than 6 billion US dollars to develop IgM antibody therapy, Sanofi reached a cooperation

04-27

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

More than $6 billion to develop IgM antibody therapy, Sanofi reaches cooperation

Related Articles

Express more than 6 billion US dollars to develop IgM antibody therapy, Sanofi reached a cooperation